Targeting androgen receptor aberrations in castration-resistant prostate cancer

Clinical Cancer Research

Volumn 22, Issue 17, 2016, Pages 4280-4282

  Sharp, Adam ^a   Welti, Jonathan ^a   Blagg, Julian ^b   De Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ENZALUTAMIDE; EPI 506; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR ANTAGONIST;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; ALTERNATIVE RNA SPLICING; ANIMAL; GENETICS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE;

ALTERNATIVE SPLICING; ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MICE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, ANDROGEN;

EID: 84988645712     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1137     Document Type: Article

References (12)

1. Yang YC, Banuelos CA, Mawji NR, Wang J, Kato M, Haile S, et al. Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer. Clin Cancer Res 2016;22:4466-77.
2. Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 2015;34:1745-57.
3. Welti J, Rodrigues DN, Sharp A, Sun S, Lorente D, Riisnaes R, et al. Analytical validation and clinical qualification of a new immunohistochemical assay for androgen receptor splice variant-7 protein expression in metastatic castration-resistant prostate cancer. Eur Urol 2016 Apr 22. [Epub ahead of print].
4. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-38.
5. Xu D, Zhan Y, Qi Y, Cao B, Bai S, Xu W, et al. Androgen receptor splice variants dimerize to transactivate target genes. Cancer Res 2015;75:3663-71.
6. Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, et al. BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Mol Cancer Res 2016;14:324-31.
7. Ferraldeschi R, Welti J, Powers MV, Yuan W, Smyth T, Seed G, et al. Second-generation HSP90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells. Cancer Res 2016;76: 2731-42.
8. Minamiguchi K, Seki M, Aoyagi H, Kajiwara D, Mori T, Masuko N, et al. TAS3681: new class of androgen receptor antagonist with androgen receptor downregulating activity. J Clin Oncol 33, 2015 (suppl 7; abstr 266).
9. Lavery DN, McEwan IJ. Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced folding. Biochemistry 2008;47:3360-9.
10. Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest 2013;123:2948-60.
11. Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, Andrews TE, et al. EPI-001 is a selective peroxisome proliferator-activated receptorgamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget 2015;6:3811-24.
12. Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov 2011;10:307-17.